



TARDIVE DYSKINESIA

RMA ID Number	Reference List for RMA473-1 as at August 2023
112819	Australian Medicines Handbook (AMH) (2023). Domperidol. Retrieved 12 April 2023, from https://amhonline.amh.net.au/chapters/gastrointestinal-drugs/antiemetics/dopamine-antagonists/droperidol-gastrointestinal
112820	Australian Medicines Handbook (AMH) (2023). Domperidone. Retrieved 16 May 2023, from https://amhonline.amh.net.au/chapters/gastrointestinal-drugs/antiemetics/dopamine-antagonists/domperidone
112821	Australian Medicines Handbook (AMH) (2023). Metoclopramide. Retrieved 18 May 2023, from https://amhonline.amh.net.au/chapters/gastrointestinal-drugs/antiemetics/dopamine-antagonists/metoclopramide
112822	Australian Medicines Handbook (AMH) (2023). Prochlorperazine. Retrieved 14 July 2023, from https://amhonline.amh.net.au/chapters/gastrointestinal-drugs/antiemetics/dopamine-antagonists/prochlorperazine
112817	Australian Medicines Handbook (AMH) (2023). Antipsychotics. Retrieved 11 April 2023, from https://amhonline.amh.net.au/chapters/psychotropic-drugs/antipsychotics
112818	Australian Medicines Handbook (AMH) (2023). Buspirone. Retrieved 19 January 2023, from https://amhonline.amh.net.au/chapters/psychotropic-drugs/drugs-anxiety-sleep-disorders/other-drugs-anxiety-sleep-disorders/buspirone
110357	Bergman H, Soares-Weiser K (2018). Anticholinergic medication for antipsychotic-induced tardive dyskinesia. <i>Cochrane Database Syst Rev</i> , 1(1): CD000204.
111428	Borison RL, Diamond BI (1980). Anticholinergics promote neuroleptic-induced tardive dyskinesia. <i>Adv Biochem Psychopharmacol</i> , 24: 359-61.
111429	Burnett GB, Prange AJ Jr, Wilson IC, et al (1980). Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. An investigation of mechanism. <i>Neuropsychobiology</i> , 6(2): 109-20.
110232	Carbon M, Hsieh CH, Kane JM, et al (2017). Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: A meta-analysis. <i>J Clin Psychiatry</i> , 78(3): e264-78.
110113	Carroll BJ, Curtis GC, Kokmen E (1977). Paradoxical response to dopamine agonists in tardive dyskinesia. <i>Am J Psychiatry</i> , 134(7): 785-9.
110038	Chatterjee K, Dangi A, Sharma R, et al (2022). Adding pre-emptive anticholinergics to antipsychotics: Is it justified? <i>Ind Psychiatry J</i> , 31(2): 370-3.
110233	Cornett EM, Novitch M, Kaye AD, et al (2017). Medication-induced tardive dyskinesia: A review and update. <i>Ochsner J</i> , 17(2): 162-74.
110234	Correll CU, Kane JM, Citrome LL (2017). Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. <i>J Clin Psychiatry</i> , 78(8): 1136-47.
110235	D'Abreu A, Friedman JH (2018). Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: Rare or non-existent: Literature review. <i>Tremor Other Hyperkinet Mov (N Y)</i> , 8: 570.

109992	Deik A, Tarsy D (2022). Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis. Retrieved 7 February 2023, from https://www.uptodate.com/contents/tardive-dyskinesia-etiology-risk-factors-clinical-features-and-diagnosis
71587	Desmarais JE, Beauclair L, Margolese HC (2012). Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? <i>J Psychopharmacol</i> , 26(9): 1167-74.
112823	Din L, Preuss CV (2022). Prochlorperazine. StatPearls - NCBI Bookshelf. Retrieved 23 May 2023, from https://www.ncbi.nlm.nih.gov/books/NBK537083/?report=printable
111430	Double DB, Warren GC, Evans M, et al (1993). Efficacy of maintenance use of anticholinergic agents. <i>Acta Psychiatr Scand</i> , 88(5): 381-4.
71586	Frei K (2019). Tardive dyskinesia: Who gets it and why. <i>Parkinsonism Relat Disord</i> , 59: 151-4.
70588	Friedman JH, D'Abreu A (2019). [Comment] Response to Letter to the Editor. <i>Tremor Other Hyperkinet Mov (N Y)</i> , 9: 630. Comment on ID: 110235.
111431	Good MI (1981). Reversibility of long-term tardive dyskinesia associated with antiparkinsonian medication: a case report. <i>Am J Psychiatry</i> , 138(8): 1112-3.
49773	Greil W, Haag H, Rosznagl G, et al (1984). Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. <i>Br J Psychiatry</i> , 145: 304-10.
41952	Hughes JR, McHugh P, Holtzman S (1998). Caffeine and schizophrenia. <i>Psychiatr Serv</i> , 49(11): 1415-7.
41352	Jankelowitz SK (2013). Treatment of neurolept-induced tardive dyskinesia. <i>Neuropsychiatr Dis Treat</i> , 9: 1371-80.
40487	Kanzaki A, Tada H, Otsuka A, et al (2019). Severe tardive dyskinesia induced by domperidone in presenile and non-dementia type 2 diabetes man with alcohol misuse showing albuminocytological dissociation and white matter hyperintensity. <i>BMJ Case Rep</i> , 12(5): e228789.
40368	Liang TW, Tarsy D (2023). Tardive dyskinesia: Prevention, treatment, and prognosis. Retrieved 17 August 2006, from https://www.uptodate.com/contents/tardive-dyskinesia-prevention-treatment-and-prognosis
40317	Macaluso M, Flynn A, Preskorn SH (2017). Tardive dyskinesia: A historical perspective. <i>J Psychiatr Pract</i> , 23(2): 121-9.
40000	Ogino S, Miyamoto S, Miyake N, et al (2014). Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. <i>Psychiatry Clin Neurosci</i> , 68(1): 37-49.
40239	Olivera AA, Kiefer MW, Manley NK (1990). Tardive dyskinesia in psychiatric patients with substance use disorders. <i>Am J Drug Alcohol Abuse</i> , 16(1-2): 57-66.
39422	Rao AS, Camilleri M (2010). Review article: metoclopramide and tardive dyskinesia. <i>Aliment Pharmacol Ther</i> , 31(1): 11-9.
106935	Revet A, Montastruc F, Roussin A, et al (2020). Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. <i>BMC Psychiatry</i> , 20(1): 308.
40010	Sewell DD, Jeste DV (1992). Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases. <i>Arch Fam Med</i> , 1(2): 271-8.
111432	Silver H, Geraisy N, Schwartz M (1995). No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. <i>J Clin Psychiatry</i> , 56(4): 167-70.
38155	Svendsen K, Wood M, Olsson E, et al (2018). Reported time to onset of neurological adverse drug reactions among different age and gender groups

	using metoclopramide: an analysis of the global database Vigibase. <i>Eur J Clin Pharmacol</i> , 74(5): 627-36.
37467	Temmingh HS, van den Brink W, Howells F, et al (2020). Methamphetamine use and antipsychotic-related extrapyramidal side-effects in patients with psychotic disorders. <i>J Dual Diagn</i> , 16(2): 208-17.
37456	Vardar MK, Ceylan ME, Unsalver BO (2020). Assessment of risk factors for tardive dyskinesia. <i>Psychopharmacol Bull</i> , 50(3): 36-46.
112824	Vasan S, Padhy RK (2023). Tardive dyskinesia. StatPearls - NCBI Bookshelf. Retrieved 15 May 2023, from https://www.ncbi.nlm.nih.gov/books/NBK448207/
37421	Walker RH (2019). [Comment] Reply to: Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: Rare or non-existent: Literature review. <i>Tremor Other Hyperkinet Mov (N Y)</i> , 9: 626. Comment on ID: 110235.
37397	Waln O, Jankovic J (2013). An update on tardive dyskinesia: from phenomenology to treatment. <i>Tremor Other Hyperkinet Mov (N Y)</i> , 3: tre-03-161-4138-1.
112825	Wilson TK, Tripp J (2023). Buspirone. StatPearls - NCBI Bookshelf. Retrieved 26 January 2023, from https://www.ncbi.nlm.nih.gov/books/NBK531477
111433	Yassa R (1985). Antiparkinsonian medication withdrawal in the treatment of tardive dyskinesia: a report of three cases. <i>Can J Psychiatry</i> , 30(6): 440-2.
37357	Zaretsky A, Rector NA, Seeman MV, et al (1993). Current cannabis use and tardive dyskinesia. <i>Schizophr Res</i> , 11(1): 3-8.